Synapse - Raajit Rampal

Search Within

Raajit Kumar Rampal

Results (338)

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study

Journal Article

Gupta, V.; Kosiorek, H. E.; Mead, A.; Klisovic, R. B.; Galvin, J. P.; Berenzon, D.; Yacoub, A.; Viswabandya, A.; Mesa, R. A.; Goldberg, J.; more...
Biology of Blood and Marrow Transplantation (2019)

Fulltext@MSK | Save

Myeloproliferative neoplasm (MPN) blastic transformation occurs at the level of hematopoietic stem cells

Meeting Abstract

Wang, X.; Hu, C. S.; Tripodi, J.; Najfeld, V.; Petersen, B.; Rampal, R. K.; Farnoud, N.; Famulare, C.; Mascarenhas, J.; Hoffman, R.
Blood (2018)

Fulltext@MSK | Save

Hematologic malignancies arising in patients with germ cell tumors: Secondary somatic differentiation of hematopoietic malignancies from germ cell precursors

Meeting Abstract

Taylor, J.; Donoghue, M.; Rampal, R. K.; Tamari, R.; Tallman, M. S.; Feldman, D. R.; Taylor, B. S.; Abdel-Wahab, O. I.
Blood (2018)

Fulltext@MSK | Save

Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents

Meeting Abstract

Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
Blood (2018)

Fulltext@MSK | Save

Prognostic impact of activating mutations of the NRAS/KRAS genes in patients with primary and post-essential thrombocythemia (ET)/polycythemia vera (PV) myelofibrosis (MF)

Meeting Abstract

Santos, F. P. S.; Getta, B.; Masarova, L.; Famulare, C.; Schulman, J.; Puga, R. D.; Paiva, R. D. A.; Hamerschlak, N.; Kantarjian, H. M.; Levine, R. L.; more...
Blood (2018)

Fulltext@MSK | Save

A novel prognostic model including cytogenetic and molecular data in patients with primary and post-essential thrombocythemia (ET)/polycythemia vera (PV) myelofibrosis (MF)

Meeting Abstract

Santos, F. P. S.; Getta, B.; Masarova, L.; Famulare, C.; Schulman, J.; Datoguia, T. S.; Goncalves, G. A. R.; Hamerschlak, N.; Kantarjian, H. M.; Levine, R. L.; more...
Blood (2018)

Fulltext@MSK | Save

Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: Initial results of a phase II study

Meeting Abstract

Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; Stein, E. M.; Kadia, T. M.; Mauro, M. J.; Pemmaraju, N.; Alvarez, K.; Ard, N.; Goodman, T.; more...
Blood (2018)

Fulltext@MSK | Save

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 randomized trial of pegylated interferon alfa-2a (PEG) versus hydroxyurea (HU) therapy for the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET)

Meeting Abstract

Mascarenhas, J.; Kosiorek, H. E.; Prchal, J. T.; Rambaldi, A.; Berenzon, D.; Yacoub, A.; Harrison, C. N.; McMullin, M. F.; Vannucchi, A. M.; Ewing, J.; more...
Blood (2018)

Fulltext@MSK | Save

Evaluation of combination tagraxofusp (SL-401) and hypomethylating agent (HMA) therapy for the treatment of chronic myelomonocytic leukemia (CMML)

Meeting Abstract

Krishnan, A.; Li, B.; Pagane, M.; McGovern, E.; Stone-Molloy, Z.; Chen, J.; Brooks, C.; Levine, R. L.; Rampal, R. K.
Blood (2018)

Fulltext@MSK | Save

Alisertib (MLN8237), an oral selective inhibitor of aurora kinase A, has clinical activity and restores GATA1 expression in patients with myelofibrosis

Meeting Abstract

Gangat, N.; Stein, B. L.; Marinaccio, C.; Swords, R.; Watts, J. M.; Gurbuxani, S.; Frankfurt, O.; Altman, J. K.; Wen, J. Q.; Farnoud, N.; more...
Blood (2018)

Fulltext@MSK | Save